Reprogramming therapeutics: iPS cell prospects for neurodegenerative disease.
The recent description of somatic cell reprogramming to an embryonic stem (ES) cell-like phenotype, termed induced pluripotent stem (iPS) cell technology, presents an exciting potential venue toward cell-based therapeutics and disease models for neurodegenerative disorders. Two recent studies (Dimos et al. and Ebert et al.) describe the initial characterization of neurodegenerative disease patient-derived iPS cell cultures as proof of concept for the utility of this technology.
Abeliovich
Asa
A
Department of Pathology, Taub Institute, Columbia University Medical Center, 630 West 168(th) Street, New York, NY 10032, USA.
Doege
Claudia A
CA
D000818:Animals; D018929:Cell Culture Techniques / Q000379:methods / Q000639:trends; D054337:Cell Dedifferentiation / Q000502:physiology*; D019070:Cell Lineage / Q000502:physiology; D053595:Embryonic Stem Cells / Q000502:physiology / Q000637:transplantation*; D006801:Humans; D019636:Neurodegenerative Diseases / Q000628:therapy*; D039904:Pluripotent Stem Cells / Q000502:physiology / Q000637:transplantation*; D033581:Stem Cell Transplantation / Q000379:methods* / Q000639:trends*; D014182:Transplantation, Autologous / Q000379:methods / Q000639:trends